Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Ralph A. DeFronzo, M.D.

Has Ralph A. DeFronzo, M.D. received an FDA warning letter? Yes. FDA issued a warning letter dated September 17, 2025 concerning products containing lixisenatide.

Letter facts

Letter date
September 17, 2025 (2025-09-17)
Issuing office
Center for Drug Evaluation and Research (CDER)
Violation categories
Other

Understanding these violation categories

Other

FDA cited violations of federal regulations governing drug research, clinical trials, or product distribution. A warning letter is an advisory notice allowing the recipient to respond.

Factual Violation Summary

FDA says seven subjects were enrolled despite not meeting protocol eligibility criteria, including blood pressure, eGFR, and exclusionary SGLT2 inhibitor/GLP-1 agonist use; the investigator also failed to promptly report a study design change to the IRB.

Active Drug Ingredients

Lixisenatide

Statutory Citations & Specific Allegations

  • Failure to ensure the investigation was conducted according to the investigational plan (21 CFR 312.60)
  • Failure to promptly report all changes in research activity to the IRB (21 CFR 312.66)

Similar violations (Other)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.